Gene: KCNAB1

7881
AKR6A3|KCNA1B|KV-BETA-1|Kvb1.3|hKvBeta3|hKvb3
potassium voltage-gated channel subfamily A member regulatory beta subunit 1
protein-coding
3q25.31
Ensembl:ENSG00000169282 MIM:601141 Vega:OTTHUMG00000158552 UniprotKB:Q14722
NG_042292.1
SNP Mapped
2   ANCO-SNPs
ND|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.185e-1 (AD)  9.932e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6767209chr3:156290184 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs1353812chr3:156189951 (GRCh38.p7)A>C / A>Tnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RAB3C0.941
KRT2220.938
GPR1580.937
MAP7D20.932
REPS20.931
REEP10.93
NMNAT20.93
NRIP30.93
CACNB40.928
GDA0.928

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.542
RAB13-0.53
MYL3-0.526
RNF135-0.516
TGIF1-0.514
AGTRAP-0.51
FLT3LG-0.505
MAGEA12-0.501
ROM1-0.495
WWTR1-0.494

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of KCNAB1 mRNA"19114083
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNAB1 mRNA"27188386
C0126064-vinyl-1-cyclohexene dioxide4-vinyl-1-cyclohexene dioxide affects the expression of KCNAB1 mRNA20829426
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNAB1 mRNA"27188386
D020106AcrylamideAcrylamide results in decreased expression of KCNAB1 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of KCNAB1 gene27153756
D000638AmiodaroneAmiodarone results in increased expression of KCNAB1 mRNA15520326
D000643Ammonium ChlorideAmmonium Chloride affects the expression of KCNAB1 mRNA16483693
D001564Benzo(a)pyreneBenzo(a)pyrene affects the expression of KCNAB1 mRNA22316170
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased mutagenesis of KCNAB1 gene25435355
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of KCNAB1 mRNA22228805
C002791bismuth tripotassium dicitratebismuth tripotassium dicitrate results in decreased expression of KCNAB1 mRNA15912405
C006780bisphenol Abisphenol A affects the expression of KCNAB1 mRNA25181051
D019256Cadmium ChlorideCadmium Chloride results in decreased expression of KCNAB1 mRNA24982889
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of KCNAB1 mRNA20938992
C018021cobaltous chloridecobaltous chloride results in increased expression of KCNAB1 mRNA21139344
D003042CocaineCocaine results in decreased expression of KCNAB1 mRNA18000554
D003042CocaineCocaine affects the expression of KCNAB1 mRNA20187946
D003471CuprizoneCuprizone results in decreased expression of KCNAB1 mRNA26577399
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of KCNAB1 mRNA23640034
D003907DexamethasoneDexamethasone results in increased expression of KCNAB1 mRNA22733784
D003907DexamethasoneDexamethasone results in decreased expression of KCNAB1 mRNA20032058
D003907DexamethasoneTestosterone inhibits the reaction [Dexamethasone results in decreased expression of KCNAB1 mRNA]20032058
D002945CisplatinCisplatin results in decreased expression of KCNAB1 mRNA27392435
D004041Dietary FatsDietary Fats results in decreased expression of KCNAB1 mRNA18042831
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of KCNAB1 mRNA17942915
D004052DiethylnitrosamineMET protein inhibits the reaction [Diethylnitrosamine results in increased expression of KCNAB1 mRNA]17942915
C118739entinostatentinostat results in decreased expression of KCNAB1 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNAB1 mRNA"27188386
D005485FlutamideFlutamide results in increased expression of KCNAB1 mRNA24793618
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of KCNAB1 mRNA20938992
D019833GenisteinGenistein results in increased expression of KCNAB1 mRNA16169203
D005839GentamicinsGentamicins results in decreased expression of KCNAB1 mRNA22061828
D006220HaloperidolHaloperidol results in decreased expression of KCNAB1 mRNA18797397
C544151jinfukangjinfukang results in decreased expression of KCNAB1 mRNA27392435
C008261lead acetate[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KCNAB1 mRNA22839698
D008627Mercuric ChlorideMercuric Chloride results in decreased expression of KCNAB1 mRNA16507785
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of KCNAB1 mRNA20938992
D008731MethoxychlorMethoxychlor affects the expression of KCNAB1 mRNA20829426
C008493methylselenic acidmethylselenic acid results in increased expression of KCNAB1 mRNA18548127
D009151Mustard GasMustard Gas results in increased expression of KCNAB1 mRNA15674843
D009532NickelNickel results in decreased expression of KCNAB1 mRNA24768652|2558310
C028007nickel monoxidenickel monoxide results in increased expression of KCNAB1 mRNA19167457
C076029olanzapineolanzapine results in decreased expression of KCNAB1 mRNA18797397
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of KCNAB1 mRNA25729387
D010100OxygenOxygen deficiency results in decreased expression of KCNAB1 mRNA26516004
D010100OxygenOxygen results in increased expression of KCNAB1 mRNA25447406
D000073878Palm OilPalm Oil results in decreased expression of KCNAB1 mRNA18042831
D011078Polychlorinated BiphenylsPolychlorinated Biphenyls affects the expression of KCNAB1 mRNA21334430
D059808PolyphenolsPolyphenols results in decreased expression of KCNAB1 mRNA16293270
D011441PropylthiouracilPropylthiouracil results in decreased expression of KCNAB1 mRNA24780913
D018038Sodium SeleniteSodium Selenite results in decreased expression of KCNAB1 mRNA18175754
D013739TestosteroneTestosterone inhibits the reaction [Dexamethasone results in decreased expression of KCNAB1 mRNA]20032058
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of KCNAB1 mRNA24680724
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of KCNAB1 mRNA25729387
D014212TretinoinTretinoin results in increased expression of KCNAB1 mRNA21934132
D014302Trinitrobenzenesulfonic AcidTrinitrobenzenesulfonic Acid results in increased expression of KCNAB1 mRNA23537331
D014635Valproic AcidValproic Acid results in increased expression of KCNAB1 mRNA24383497|2800136
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of KCNAB1 gene25560391
C017803zinc protoporphyrin[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KCNAB1 mRNA22839698

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004033aldo-keto reductase (NADP) activity-ISS-  
GO:0005249voltage-gated potassium channel activity-IEA-  
GO:0015459potassium channel regulator activity-IDA7890032  12130714  
GO:0019904protein domain specific binding-IPI10585425  
GO:0044325ion channel binding-IEA-  
GO:0070402NADPH binding-IDA17540341  
GO ID GO Term Qualifier Evidence PubMed
GO:0006813potassium ion transport-TAS7499366  
GO:0007420brain development-IEA-  
GO:0007507heart development-IEA-  
GO:0007519skeletal muscle tissue development-IEA-  
GO:0007611learning or memory-IEA-  
GO:0045445myoblast differentiation-IEA-  
GO:0055114oxidation-reduction process-ISS-  
GO:0060539diaphragm development-IEA-  
GO:0071805potassium ion transmembrane transport-IEA-  
GO:1901379regulation of potassium ion transmembrane transport-IDA7890032  
GO:1902259regulation of delayed rectifier potassium channel activity-ISS-  
GO:1902260negative regulation of delayed rectifier potassium channel activity-IEA-  
GO:1903817negative regulation of voltage-gated potassium channel activity-IMP10585425  
GO ID GO Term Qualifier Evidence PubMed
GO:0005829cytosol-IDA17540341  
GO:0005886plasma membrane-TAS-  
GO:0008076voltage-gated potassium channel complex-IMP10585425  
GO:0031234extrinsic component of cytoplasmic side of plasma membrane-IDA17540341  
GO:0032839dendrite cytoplasm-IEA-  
GO:0034705potassium channel complex-IDA12130714  
GO:0043204perikaryon-IEA-  
GO:0044224juxtaparanode region of axon-IEA-  
GO:1990635proximal dendrite-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemTAS
R-HSA-1296071Potassium ChannelsTAS
R-HSA-1296072Voltage gated Potassium channelsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal